STOCKHOLM, March 6, 2025 /PRNewswire/ — Autoliv, Inc. (NYSE: ALV) and (SSE: ALIV.sdb), the worldwide leader in automotive safety systems, invites financial analysts, institutional investors, and journalists to its 2025 Capital Markets Day event, “Leading the Way”.

Autoliv invites financial analysts, institutional investors and journalists with a focus on automotive safety technology to its Capital Markets Day, on Wednesday, June 4, 2025, in Stockholm, Sweden. We are looking forward to sharing more about our journey towards our targets and how we capture growth opportunities.

The “Leading the Way” event will focus on Autoliv’s medium and long-term growth avenues, products and solutions, strategic roadmap, and progress in automation and operational efficiency. Autoliv management will present how Autoliv works strategically with OEMs, securing a strong position with future winners which will support Autoliv’s long term success.

The day will be hosted by Autoliv President & CEO, Mikael Bratt. “Leading the Way” will feature presentations from members of the Autoliv Executive Management Team, exhibitions of Autoliv’s latest innovations and technologies, and opportunities to view and try out new and exciting vehicle models from innovative vehicle manufacturers.        

followed by                                               

• Meet-and-Greet with Autoliv team members
• Experience Product Exhibition, Tech show and Customer Collaboration Exhibits including test drives
• Boat tour to Central Stockholm for dinner at the Vasa Museum for registered guests

A formal invitation with an official agenda, registration site, and other relevant information will be released in April. Information will also later be available on the Autoliv website www.autoliv.com.                                

We look forward to welcoming you to the lovely capital city of Sweden and home of our global headquarters.

Contact details: 
Anders Trapp
Anders.Trapp@autoliv.com
+46-709578171

About Autoliv

Autoliv, Inc. (NYSE: ALV); (Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2024, our products saved approximately 37,000 lives and reduced around 600,000 injuries.

We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 65,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2024 amounted to $10.4 billion. For more information go to Home | Autoliv.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/autoliv/r/autoliv-capital-markets-day-new-date–june-4–2025,c4114881

The following files are available for download:

• The first patient has been dosed with EVM16 at Peking University Cancer Hospital, marking a major milestone as Everest’s proprietary AI-based tumor neoantigen prediction algorithm and clinically validated mRNA platform progress into human trials.
• In preclinical studies, EVM16 demonstrated significant tumor growth inhibition in syngeneic mouse model, with repeated dosing showing favorable safety and tolerability.
• Preclinical data also showed a synergistic anti-tumor effect when EVM16 was combined with a PD-1 antibody, supporting its potential use in combination therapies in clinical settings.

SHANGHAI, March 6, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been dosed with the Company’s internally developed personalized mRNA cancer vaccine EVM16 at Peking University Cancer Hospital in the investigator-initiated clinical trial (IIT) EVM16CX01. EVM16CX01 is the first-in-human (FIH) trial for EVM16, conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer center, to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in patients with advanced or recurrent solid tumors.

EVM16 is a novel personalized therapeutic mRNA cancer vaccine internally developed by Everest. It contains neoantigens with high immunogenicity potential, predicted based on the unique tumor mutations of each patient using Everest’s proprietary AI-based neoantigen prediction algorithm, EVER-NEO-1. The vaccine is designed to encode dozens of tumor neoantigens. The vaccine uses a lipid nanoparticle (LNP) delivery system to efficiently deliver neoantigen-encoded mRNA in vivo, activating neoantigen-specific tumor-killing T cells and inhibiting tumor growth.

In preclinical studies, vaccination with EVM16 stimulated a strong neoantigen-specific T cell response in different mouse models and showed significant tumor growth inhibition in the syngeneic B16F10 mouse melanoma model. EVER-NEO-1, the AI-based neoantigen prediction algorithm developed in-house by Everest, can identify the majority of reported tumor neoantigens, as well as several previously unreported neoantigens. Furthermore, the neoantigen prediction capability of EVER-NEO-1 was shown to be either comparable to or superior to leading industry algorithms in multiple independent validation studies.

Preclinical data also demonstrated that the combination of EVM16 and a PD-1 antibody has synergistic effects, which supports the combination of EVM16 with checkpoint inhibitors in clinical settings. In preclinical toxicity studies, repeated dosing with EVM16 was well tolerated and safe. Taken together, the preclinical studies show that EVM16 is safe and efficacious and has potential to bring benefits to cancer patients. 

“The first patient dosed with the personalized mRNA cancer vaccine EVM16 represents a notable milestone in its clinical development. EVM16 is a customized vaccine based on each patient’s tumor-specific mutations, and using the cutting-edge mRNA technology, to activate the patient’s tumor-specific immune response to recognize and attack tumor cells.” said Professor Shen Lin, Director of the Gastrointestinal Oncology Department at Beijing Cancer Hospital and Chair of the Gastric Cancer Expert Committee of the Chinese Society of Clinical Oncology. ” In preclinical studies, we are excited to discover that EVM16, when combined with PD-1 antibodies, demonstrated synergistic anti-tumor effects, further highlighting its broader potential for clinical application. We are confident in achieving positive outcomes in the upcoming clinical trials, bringing hope to cancer patients.”

“In recent years, AI has become a major force in drug development, especially in the area of mRNA vaccines. AI is increasingly seen as a crucial tool for boosting research efficiency and accuracy, attracting substantial attention from both the biopharmaceutical industry and governments worldwide. Everest has demonstrated the clinical validation capabilities of its mRNA platform since 2021, with an emphasis on employing AI to identify tumor neoantigens. By continually optimizing its algorithms, the company has enhanced the precision of neoantigen recognition and validation, giving it a strong foundation and a competitive edge in developing mRNA-based cancer vaccines.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “EVM16 is the first personalized mRNA cancer vaccine internally developed by Everest. The first patient dosing marks a significant milestone in its clinical development of EVM16, indicating our proprietary tumor neoantigen AI-based algorithm system and mRNA technology platform have advanced to human trials. As a cancer vaccine candidate developed using our proprietary mRNA platform, we look forward to demonstrating EVM16’s therapeutic potential in upcoming clinical trials, with the goal of offering innovative treatment options to cancer patients worldwide and expand choices for those facing life-threatening diseases.”

According to the Globocan’s data in 2022, there were 19.976 million new cancer cases globally, with 9.744 million cancer-related deaths¹. Immunotherapy including checkpoint inhibitors has become an important part of treating some cancer types. However, they are only effective for some patients, and there is an urgent need to develop new generations of immunotherapies, such as personalized mRNA cancer vaccines, that have demonstrated early promise in clinical setting.  

Everest Medicines is currently developing a range of mRNA cancer therapeutics, including personalized cancer vaccines (PCVs), tumor-associated antigen (TAA) vaccines, immunomodulatory cancer vaccines, etc. Additionally, the company is working on next-generation lipid nanoparticle (LNP) delivery systems to enhance cell-mediated immune responses.  Everest Medicines will submit an investigational new drug application for its TAA vaccines in China and the United States in 2025.

About EVM16

EVM16 is a novel personalized mRNA cancer vaccine independently developed by Everest Medicines. EVM16 contains neoantigens with high immunogenicity potential and predicted by Everest-proprietary algorithm EVER-NEO-1 and uses an LNP delivery system to efficiently deliver neoantigen-expressing mRNAs into the human body. After vaccination with EVM16, neoantigens-encoding mRNAs are delivered into human body to produce neoantigen peptides, which activate neoantigen-specific T cell immune responses to kill tumor cells, thereby inhibiting tumor growth.

About EVM16CX01 study

The study is a FIH, dose escalation and expansion study to evaluate the safety, tolerability, immunogenicity, and initial efficacy of EVM16 injection as a single and in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors. The primary objectives are to evaluate the safety and tolerability of EVM16 monotherapy and EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors, and to determine the recommended phase 2 dose (RP2D) of EVM16. The secondary objectives are to evaluate the immunogenicity of EVM16, and the initial efficacy of EVM16 in combination with PD-1 antibody in subjects with advanced or recurrent solid tumors.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com. 

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Reference:

1.     Globocan 2022: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf. 

BEIJING, March 6, 2025 /PRNewswire/ — By China Report ASEAN:

As we wrapped up the year 2024 and prepared for 2025, China International Communications Group’s Center for Asia-Pacific joined hands with the Institute of Asian Studies of China Foreign Affairs University and Guangxi University to recount the biggest moments in the passing year and chose the top 10 stories of China-ASEAN cooperation in 2024. The top 10 stories were first released in Nanning, Guangxi Province on February 27.

1. Third Plenary Session of the 20th Central Committee of the Communist Party of China (CPC) receives warm response from across ASEAN
   The Third Plenary Session of the 20th CPC Central Committee held in July 2024 marked a new milestone in China’s efforts to advance reform in the new era. All sectors in ASEAN followed this meeting closely. They spoke highly of the Resolution of the CPC Central Committee on Further Deepening Reform Comprehensively to Advance Chinese Modernization adopted at the meeting. Many recognized it as a milestone gathering in the process of China’s reform and opening up which demonstrated the determination of the CPC to comprehensively deepen reform and opening up even further along the path to modernization while also creating important opportunities and major dividends for all countries in the world, especially neighboring countries in Southeast Asia, and injecting new impetus into the common development of the region. 
2. Premier Li Qiang attends Leaders’ Meetings on East Asia Cooperation in Laos
   On October 10, Chinese Premier Li Qiang attended the 27th China-ASEAN Summit in Vientiane, Laos. In his speech, Li remarked that the China-ASEAN relationship has moved far beyond the bilateral scope and taken on great significance for Asia and the world. China seeks to work hand-in-hand with ASEAN to jointly create a better future for Asia. First, it seeks to create a multidimensional connectivity network, enhance infrastructure cooperation with ASEAN, and expedite the signing and implementation of the 3.0 version of the China-ASEAN Free Trade Area (CAFTA 3.0). Second, moves will be made to expand cooperation in emerging industries, tap the cooperation potential in areas such as the digital economy and green development, and accelerate the digital transformation of traditional industries. Third, it will deepen people-to-people and cultural exchanges and promote implementation of the Global Civilization Initiative in the region.    
3. A wave of high-level visits by Southeast Asian countries to China
   In 2024, the top leaders of the 10 ASEAN member states and East Timor visited China successively, culminating in an unprecedented wave of visits to China. Among them, Indonesian President Prabowo Subianto visited China in his first overseas trip right after he was elected in March and chose China as the first country to visit after taking office, attracting tremendous attention. The intensive exchange of high-level visits has played an important role in China-ASEAN cooperation for a shared future. The visits have empowered the two sides to actively carry out friendly cooperation, continuously enhance mutual understanding and trust, and jointly achieve development and revitalization, injecting stability and positive energy into regional peace and development.
4. Negotiations on the 3.0 version of the China-ASEAN Free Trade Area (CAFTA 3.0) wrap up
   On October 10, the leaders of China and the 10 ASEAN member states announced the substantial conclusion of negotiations on CAFTA 3.0 and issued the Joint Statement on the Substantial Conclusion of the CAFTA 3.0 Upgrade Negotiations. The upgraded version covers both the existing areas of the CAFTA and emerging areas with great potential for cooperation between the two sides, which is of great pioneering significance. China and the ASEAN member states agree that the substantial conclusion of the CAFTA 3.0 upgrade negotiations demonstrates their firm commitment to upholding a rules-based trading environment, deepening economic integration and practical cooperation in a complex global environment, and accelerating post-pandemic economic recovery. 
5. China-ASEAN trade reaches new heights, with both sides remaining each other’s largest trading partner
   In 2024, the total trade value between China and ASEAN reached 6.99 trillion yuan (US$962.98 billion), up 9.0 percent, accounting for 15.9 percent of China’s total foreign trade. Its exports to ASEAN reached 4.17 trillion yuan (US$575 billion), up 13.4 percent, and its imports from ASEAN reached 2.82 trillion yuan (US$388.88 billion), up 3.2 percent. Denominated in US dollars, the total value of China-ASEAN trade was US$982.34 billion, up 7.8 percent. Chinese exports to ASEAN were US$586.52 billion, up 12.0 percent, and Chinese imports from ASEAN were US$395.81 billion, up 2.0 percent. China has always taken concrete actions to support East Asia cooperation and regional economic integration. It has strengthened industrial chain cooperation with ASEAN, with imports from and exports to ASEAN having grown for nine consecutive years. ASEAN has remained China’s largest trading partner for five consecutive years, and China has remained ASEAN’s largest trading partner for 16 consecutive years.
6. The China-ASEAN Year of People-to-People Exchanges yields fruitful results
   In September 2023, to commemorate the 10th anniversary of President Xi Jinping proposing the building of an even closer China-ASEAN community with a shared future, China and ASEAN jointly announced that 2024 would be designated as the China-ASEAN Year of People-to-people Exchanges. Both sides placed the preparations and arrangements for the Year of People-to-People Exchanges high on the agenda. The various activities effectively promoted people-to-people and cultural exchanges in various fields and helped people on both sides enhance mutual understanding and friendship. On October 10, the leaders of the two sides jointly released the China-ASEAN Joint Statement on Deepening Cooperation in People-to-People Exchanges, which affirmed the achievements of the Year of People-To-People Exchange and agreed to extend the China-ASEAN Year of People-to-People Exchanges to 2025. 
7. China and ASEAN continue to deepen cross-border payment cooperation
   At the 27th China-ASEAN Summit, Chinese Premier Li Qiang indicated that China stands ready to strengthen the linkage of cross-border payment systems with ASEAN. Cross-border QR code payment connectivity has already been realized between the payment institutions of China and many ASEAN countries. A China-ASEAN cross-border trade and financial connectivity platform was officially launched at the China-ASEAN Financial Cooperation and Development Conference 2024, marking new progress in building a smart system for China-ASEAN cross-border trade and finance. All sides are now working to deepen China-ASEAN cross-border payment connectivity and enhance cooperation in infrastructure, product services, technical support, and legal supervision to ensure strong support for economic and trade cooperation and personnel exchanges while promoting regional economic integration and prosperity.
8. China and ASEAN accelerate connectivity to elevate regional cooperation to new heights
   In 2024, China and ASEAN achieved fruitful results in connectivity. The annual freight train trips along the New International Land-Sea Trade Corridor (NILSTC) exceeded 10,000 for the first time. ASEAN Express freight train service was successfully launched, realizing seamless connection of the two major trade channels of the NILSTC and the China-Europe Express freight train service and creating new arteries for Eurasian trade. At the same time, significant progress was achieved with the pan-Asia railway network: round-trip freight train service commenced on the China–Laos–Thailand–Malaysia cross-border railway for the first time, the volume of goods transported across borders on the China-Laos Railway surpassed 10 million tons, the Lao section of the China-Laos Railway set numerous records of the average daily passenger flow, China and Vietnam officially signed an intergovernmental agreement on a cross-border standard-gauge railway cooperation project, and Chinese and Malaysian companies signed an agreement on operation and maintenance of Malaysia’s East Coast Rail Link and announced plans for the Electric Multiple Unit train design. These achievements in connectivity have not only promoted traffic convenience in the region, but also helped lift China-ASEAN cooperation to new heights.   
9. The Regional Comprehensive Economic Partnership (RCEP) Support Unit (RSU) officially begins operation 
   On December 9, the RCEP Support Unit (RSU) was officially inaugurated at the ASEAN Secretariat. As the non-ASEAN rotating chair of RCEP in 2024, China worked with ASEAN chair Indonesia to actively lead the 15 parties to establish the RSU as scheduled. The full operation of the RSU is an important milestone in the development of RCEP mechanism and a solid step towards the concrete goal of establishing a separate RCEP secretariat, which is conducive to providing adequate secretarial and technical support for basic implementation of RCEP and promoting full and high-quality implementation.
10. China-ASEAN Expo (CAEXPO) enters a new stage of development
    From September 24 to 28, the 21st CAEXPO took place in Nanning, Guangxi, with the theme “Upholding amity, sincerity, mutual benefit, and inclusiveness for common development, creating a diamond crown new future—promoting development of a China-ASEAN Free Trade Area 3.0 and high-quality growth of the region.” The scale of participation by ASEAN member states continued to exceed all domestic and international exhibitions. The latest CAEXPO made new achievements in the following 10 aspects: development of friendly relations, empowerment of innovative action, orders on trade transactions, results of investment cooperation, impetus for implementation of CAFTA 3.0, the effects of institutional opening, the effects of the “Nanning Channel,” a platform for the “Never-Ending CAEXPO,” people-to-people and cultural exchanges, and expansion of the influence of CAEXPO.